Bevacizumab-treated pregnant rats may constitute an experimental model for studying preeclampsia

Basit Öğe Kaydı
dc.contributor.authorBoztosun, Abdullah
dc.contributor.authorOlgan, Şafak
dc.contributor.authorÖzer, Hatice
dc.contributor.authorAtılgan, Remzi
dc.contributor.authorPala, Şehmus
dc.date.accessioned2024-10-26T17:41:15Z
dc.date.available2024-10-26T17:41:15Z
dc.date.issued2018
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPurpose: To develop a rat model of preeclampsia by administering bevacizumab, an angiogenesis inhibitor.Materials and methods: Sixteen pregnant rats were randomly allocated to intraperitoneal injection of 10 mg/kgbevacizumab or 0.1 cc intraperitoneal serum physiologic on the 4th and 8th days of gestation. Blood pressure,body weight, and proteinuria were measured on both day 0 (D0) and day 20 (D20). Blood samples were collectedon D20 for analysis, including for determining vascular endothelial growth factor (VEGF) and soluble Fms-liketyrosine kinase 1 (sFlt-1) levels. On the same day, the mice were euthanized, the placentas and pups wereweighted, and the angiogenesis markers and microvessel density were evaluated using immunohistochemicalmethods.Results: Lower serum VEGF (p=0.038) and higher SFlt-1 (p=0.015) levels were observed in bevacizumabtreated pregnant rats. Bevacizumab-treated pregnant rats had significantly higher systolic (p=0.050) anddiastolic (p = 0.046) blood pressures compared to the controls. Additionally, the bevacizumab group showed asignificant increase in proteinuria on D20 compared to that on D0 (p=0.026). Although higher serum AST, ALT,BUN, and creatinine levels and renal glomerular endotheliosis scores as well as lower placental VEGF andmicrovessel density were noted in bevacizumab-treated rats, these differences were not statistically significant(p > 0.05 for each).Conclusion: The promising results of this trial show that bevacizumab treatment in pregnant rats might providea model to study human preeclampsia.
dc.identifier.doi10.31362/patd.451705
dc.identifier.endpage308
dc.identifier.issn1309-9833
dc.identifier.issn1308-0865
dc.identifier.issue3
dc.identifier.startpage301
dc.identifier.trdizinid325639
dc.identifier.urihttps://doi.org/10.31362/patd.451705
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/325639
dc.identifier.urihttps://hdl.handle.net/20.500.12418/24383
dc.identifier.volume11
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofPamukkale Tıp Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleBevacizumab-treated pregnant rats may constitute an experimental model for studying preeclampsia
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu